These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 11412980)

  • 21. The synthesis and biological activity of a novel series of diazepine MMP inhibitors.
    Levin JI; DiJoseph JF; Killar LM; Sung A; Walter T; Sharr MA; Roth CE; Skotnicki JS; Albright JD
    Bioorg Med Chem Lett; 1998 Oct; 8(19):2657-62. PubMed ID: 9873598
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of 3-OH-3-methylpipecolic hydroxamates: potent orally active inhibitors of aggrecanase and MMP-13.
    Noe MC; Natarajan V; Snow SL; Wolf-Gouveia LA; Mitchell PG; Lopresti-Morrow L; Reeves LM; Yocum SA; Otterness I; Bliven MA; Carty TJ; Barberia JT; Sweeney FJ; Liras JL; Vaughn M
    Bioorg Med Chem Lett; 2005 Jul; 15(14):3385-8. PubMed ID: 15953722
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro phase I cytochrome P450 metabolism, permeability and pharmacokinetics of SB639, a novel histone deacetylase inhibitor in preclinical species.
    Venkatesh PR; Goh E; Zeng P; New LS; Xin L; Pasha MK; Sangthongpitag K; Yeo P; Kantharaj E
    Biol Pharm Bull; 2007 May; 30(5):1021-4. PubMed ID: 17473456
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel and selective imidazole-containing biphenyl inhibitors of protein farnesyltransferase.
    Curtin ML; Florjancic AS; Cohen J; Gu WZ; Frost DJ; Muchmore SW; Sham HL
    Bioorg Med Chem Lett; 2003 Apr; 13(7):1367-71. PubMed ID: 12657284
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of beta-benzamido hydroxamic acids as potent, selective, and orally bioavailable TACE inhibitors.
    Duan JJ; Chen L; Lu Z; Xue CB; Liu RQ; Covington MB; Qian M; Wasserman ZR; Vaddi K; Christ DD; Trzaskos JM; Newton RC; Decicco CP
    Bioorg Med Chem Lett; 2008 Jan; 18(1):241-6. PubMed ID: 18032037
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The discovery of MK-0674, an orally bioavailable cathepsin K inhibitor.
    Isabel E; Bateman KP; Chauret N; Cromlish W; Desmarais S; Duong LT; Falgueyret JP; Gauthier JY; Lamontagne S; Lau CK; Léger S; LeRiche T; Lévesque JF; Li CS; Massé F; McKay DJ; Mellon C; Nicoll-Griffith DA; Oballa RM; Percival MD; Riendeau D; Robichaud J; Rodan GA; Rodan SB; Seto C; Thérien M; Truong VL; Wesolowski G; Young RN; Zamboni R; Black WC
    Bioorg Med Chem Lett; 2010 Feb; 20(3):887-92. PubMed ID: 20061146
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heteroaryl and cycloalkyl sulfonamide hydroxamic acid inhibitors of matrix metalloproteinases.
    Levin JI; Gu Y; Nelson FC; Zask A; DiJoseph JF; Sharr MA; Sung A; Jin G; Cowling R; Chanda P; Cosmi S; Hsiao CL; Edris W; Wilhelm J; Killar LM; Skotnicki JS
    Bioorg Med Chem Lett; 2001 Jan; 11(2):239-42. PubMed ID: 11206468
    [TBL] [Abstract][Full Text] [Related]  

  • 28. General synthesis of alpha-substituted 3-bisaryloxy propionic acid derivatives as specific MMP inhibitors.
    Chollet AM; Le Diguarher T; Murray L; Bertrand M; Tucker GC; Sabatini M; Pierré A; Atassi G; Bonnet J; Casara P
    Bioorg Med Chem Lett; 2001 Feb; 11(3):295-9. PubMed ID: 11212095
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of matrix metalloproteinase inhibitors in cancer therapy.
    Hidalgo M; Eckhardt SG
    J Natl Cancer Inst; 2001 Feb; 93(3):178-93. PubMed ID: 11158186
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics and tissue distribution of Kendine 91, a novel histone deacetylase inhibitor, in mice.
    Otaegui D; Rodríguez-Gascón A; Zubia A; Cossío FP; Pedraz JL
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):153-9. PubMed ID: 19002463
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of potent and selective succinyl hydroxamate inhibitors of matrix metalloprotease-3 (stromelysin-1).
    Fray MJ; Dickinson RP
    Bioorg Med Chem Lett; 2001 Feb; 11(4):571-4. PubMed ID: 11229774
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human.
    Salphati L; Pang J; Plise EG; Lee LB; Olivero AG; Prior WW; Sampath D; Wong S; Zhang X
    Drug Metab Dispos; 2012 Sep; 40(9):1785-96. PubMed ID: 22696419
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The discovery of anthranilic acid-based MMP inhibitors. Part 3: incorporation of basic amines.
    Levin JI; Chen JM; Du MT; Nelson FC; Wehr T; DiJoseph JF; Killar LM; Skala S; Sung A; Sharr MA; Roth CE; Jin G; Cowling R; Di L; Sherman M; Xu ZB; March CJ; Mohler KM; Black RA; Skotnicki JS
    Bioorg Med Chem Lett; 2001 Nov; 11(22):2975-8. PubMed ID: 11677139
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MMPs inhibitors: new succinylhydroxamates with selective inhibition of MMP-2 over MMP-3.
    Marcq V; Mirand C; Decarme M; Emonard H; Hornebeck W
    Bioorg Med Chem Lett; 2003 Sep; 13(17):2843-6. PubMed ID: 14611841
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Substituted pyrazolopyridopyridazines as orally bioavailable potent and selective PDE5 inhibitors: potential agents for treatment of erectile dysfunction.
    Yu G; Mason H; Wu X; Wang J; Chong S; Beyer B; Henwood A; Pongrac R; Seliger L; He B; Normandin D; Ferrer P; Zhang R; Adam L; Humphrey WG; Krupinski J; Macor JE
    J Med Chem; 2003 Feb; 46(4):457-60. PubMed ID: 12570368
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery and biological evaluation of potent dual ErbB-2/EGFR tyrosine kinase inhibitors: 6-thiazolylquinazolines.
    Gaul MD; Guo Y; Affleck K; Cockerill GS; Gilmer TM; Griffin RJ; Guntrip S; Keith BR; Knight WB; Mullin RJ; Murray DM; Rusnak DW; Smith K; Tadepalli S; Wood ER; Lackey K
    Bioorg Med Chem Lett; 2003 Feb; 13(4):637-40. PubMed ID: 12639547
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MMP-13 selective α-sulfone hydroxamates: a survey of P1' heterocyclic amide isosteres.
    Barta TE; Becker DP; Bedell LJ; Easton AM; Hockerman SL; Kiefer J; Munie GE; Mathis KJ; Li MH; Rico JG; Villamil CI; Williams JM
    Bioorg Med Chem Lett; 2011 May; 21(10):2820-2. PubMed ID: 21507637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.
    Aranapakam V; Grosu GT; Davis JM; Hu B; Ellingboe J; Baker JL; Skotnicki JS; Zask A; DiJoseph JF; Sung A; Sharr MA; Killar LM; Walter T; Jin G; Cowling R
    J Med Chem; 2003 Jun; 46(12):2361-75. PubMed ID: 12773041
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The evolution of the matrix metalloproteinase inhibitor drug discovery program at abbott laboratories.
    Wada CK
    Curr Top Med Chem; 2004; 4(12):1255-67. PubMed ID: 15320725
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of PAT-1102, a novel, potent and orally active histone deacetylase inhibitor with antitumor activity in cancer mouse models.
    Hiriyan J; Shivarudraiah P; Gavara G; Annamalai P; Natesan S; Sambasivam G; Sukumaran SK
    Anticancer Res; 2015 Jan; 35(1):229-37. PubMed ID: 25550555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.